Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 5 | EJNMMI Radiopharmacy and Chemistry

Fig. 5

From: Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [111In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer

Fig. 5

A SDS-PAGE analysis on a 4–20% Tris HCl gradient mini-gel of trastuzumab or BnDTPA-trastuzumab-NLS from kit lot 17N014 after storage at 2–8 °C for 661 d, under non-reducing conditions (lanes 1 and 2, respectively) or reducing (DTT) conditions (lanes 3 and 4 respectively). MW: broad range molecular weight standards. The gel was stained with Coomassie R-250 Brilliant Blue. B SE-HPLC analysis of BnDTPA-trastuzumab-NLS from kit lot 17N014 after storage at 2–8 °C for 661 d on a BioSep SEC-s4000 column (Phenomenex, Torrance, CA, USA) eluted with 100 mM NaH2PO4 buffer, pH 7.0 at a flow rate of 0.8 mL/min with UV detection at 280 nm. BnDTPA-trastuzumab-NLS exhibited one major peak with retention time (tR = 11.7 min) and a second peak at tR = 10.7 min

Back to article page